Abstract
Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 45-49 |
| Number of pages | 5 |
| Journal | Journal of Clinical Virology |
| Volume | 109 |
| DOIs | |
| Publication status | Published - Dec 1 2018 |
Fingerprint
Keywords
- Antiretroviral therapy
- Dolutegravir
- HIV
- Semen
- Sexual transmission
ASJC Scopus subject areas
- Virology
- Infectious Diseases
Cite this
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen. / Fabrizio, Claudia; de Gennaro, Nicolò; Volpe, Anna; Scudeller, Luigia; Lagioia, Antonella; Falasca, Katia; Ladisa, Nicoletta; Angarano, Gioacchino; Monno, Laura; Saracino, Annalisa.
In: Journal of Clinical Virology, Vol. 109, 01.12.2018, p. 45-49.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen
AU - Fabrizio, Claudia
AU - de Gennaro, Nicolò
AU - Volpe, Anna
AU - Scudeller, Luigia
AU - Lagioia, Antonella
AU - Falasca, Katia
AU - Ladisa, Nicoletta
AU - Angarano, Gioacchino
AU - Monno, Laura
AU - Saracino, Annalisa
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.
AB - Background and objectives: We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma. Study design: In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment. Results: Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p < 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen. Conclusions: DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.
KW - Antiretroviral therapy
KW - Dolutegravir
KW - HIV
KW - Semen
KW - Sexual transmission
UR - http://www.scopus.com/inward/record.url?scp=85056820807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056820807&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2018.11.002
DO - 10.1016/j.jcv.2018.11.002
M3 - Article
VL - 109
SP - 45
EP - 49
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
SN - 1386-6532
ER -